Mission COVID Suraksha Scheme ,Mission Objectives All you need to know

Mission COVID Suraksha

Mission COVID Suraksha Overview

 Mission COVID Suraksha Scheme .The government launched ‘Mission COVID Suraksha’ on Wednesday, which will aid in the development of five to six COVID-19 vaccine candidates. Starting with the vaccines’ research and development, the mission will assist them in obtaining a licence and, finally, introducing them to the market. As several vaccines near the end of their trials, this mission will ensure that enough doses of these vaccine shots are available once they are approved.

Mission COVID Suraksha was established to aid in the development of accessible and affordable COVID-19 vaccines for India. Through a stimulus package, the government announced financial assistance for vaccine development. As a result, it is known as the Indian COVID-19 Vaccine Development Mission.

The mission’s Phase-I grant was Rs. 900 crores for a period of twelve months. The funds were allocated to DBT, India’s Department of Biotechnology, for the research and development of the Covid-19 vaccine.

The mission’s primary goal was to promote the development of the Covid-19 vaccine at both the pre-clinical and clinical levels. The approved fund was used to develop, manufacture, and distribute vaccines at a low cost.

The mission is carried out by a unit of BIRAC, the Biotechnology Industry Research Assistance Council, which is dedicated to the Mission COVID Suraksha.

The grant package was announced during the third stimulus under Mission COVID Suraksha.

What exactly is COVID Suraksha Mission?

  • The Indian government has approved Rs.900 crores for Phase I of Mission COVID Suraksha, which will last 12 months.
  • This mission will hasten the development of approximately 5-6 coronavirus vaccines. However, DBT has so far supported a total of ten vaccine candidates.
  • The vaccine’s preclinical and clinical development must be prioritized in order for it to be released quickly and to limit the spread of the Novel coronavirus in the country.
  • With an end-to-end focus on preclinical development, clinical development, manufacturing, and regulatory facilitation for deployment, all available and funded resources would be consolidated towards accelerated product development.
  • The Department of Biotechnology will fund the research and development (R&D) of the Indian COVID-19 vaccine (DBT)
  • It will be carried out by a Mission Implementation Unit within the Biotechnology Industry Research Assistance Council (BIRAC)
  • One of the most important goals of the country’s government is to develop an indigenous, affordable, and accessible vaccine to combat the spread of the coronavirus. This mission’s success will complement the Indian aspiration of the Atmanirbhar Bharat Abhiyan.

Mission Purposes

  •  Accelerating pre-clinical and clinical development; licencing of COVID-19 vaccine candidates in clinical trials or about to enter clinical trials.development.
  • Establishing clinical trial sites and strengthening existing immunology laboratories, central labs, and suitable facilities for animal studies, production facilities, and other testing facilities to aid in the development of the COVID-19 vaccine.
  • Facilitating training and regulatory submissions in order to accelerate clinical development and licensure of COVID-19 vaccine candidates with identified targets.
  • Capabilities for process development, cell line development, and GMP batch production for animal toxicology studies and clinical trials.
  • Creation of a suitable Target Product Profile so that vaccines can be developed

Important Information

  • Mission COVID Suraksha was announced as part of the Atmanirbhar Bharat 3.0 Mission to accelerate the development and production of indigenous COVID vaccines.
  • The Department of Biotechnology is implementing this at the Biotechnology Industry Research Assistance Council, BIRAC, in New Delhi.
  • Under the Mission, the Department of Biotechnology provided financial support to vaccine manufacturing facilities in order to increase the capacity of indigenous Covaxin production.

What were the potential vaccines?

The goal of Mission COVID Suraksha was to administer a total of ten vaccines, but not all of them were successful in human trials. An important part of the mission is ensuring that the vaccines are safe and ready for human use. Successful vaccine candidates included:

  • Sputnik V is a Russian vaccine named after the first artificial Earth satellite, Sputnik-I. It was also the first vaccine to be approved for use worldwide.
  • Covaxin is an Indian vaccine developed by Bharat Biotech and the ICMR (Indian Council ofMedical Research).
  • This, too, is an Indian vaccine developed by the pharmaceutical company Zydus. BNT162b2 – is developed by Pfizer with the National Biopharma Mission of the Department of Biotechnology (DBT) and has proven to be one of the few very successful ones.
  • Pfizer successfully completed all trials and began distribution very soon after its development.

Oxford-AstraZeneca created Covishield, which was manufactured at the Serum Institute of India.
The mission of Mission COVID Suraksha was to provide effective vaccines to India’s 1.4 billion people. In the midst of a pandemic where vaccines were desperately needed, the initiative was critical in bringing vaccines such as Covaxin, Covishield, and others to public health systems as soon as possible.

1)What exactly is the Corbevax Vaccine?
Corbevax is the country’s first Receptor Binding Domain (RBD) protein subunit vaccine.

It is manufactured by the Hyderabad-based Biological E. It received funding from the Biotechnology Industry Research Assistance Council (BIRAC) from the pre-clinical stage through Phase III clinical trials.

Financial Support: The vaccine received financial support from the National Biopharma Mission through the COVID-19 Research Consortium. Later, assistance was provided through Mission COVID Suraksha.

2)What exactly is a Receptor Binding Domain (RBD)?
A receptor-binding domain (RBD) is a critical component of a virus that is found on its’spike’ domain and allows it to dock to body receptors to gain entry into cells and cause infection. These are also the primary targets for viral infection prevention and treatment, including the virus that causes COVID-19.

3)What is the name of the Indian COVID-19 vaccine?
Bharat Biotech is developing COVAXINTM, India’s indigenous COVID-19 vaccine, in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology.

4)Covishield is what kind of vaccine is it?
1. What is the COVISHIELDTM vaccine? It is a replication-deficient chimp adenovirus vector that encodes the SARS-CoV-2 Spike (S) glycoprotein. Following administration, the genetic material of a portion of the Corona virus is expressed, inducing an immune response.

5)Which is more effective, Covishield or Covaxin?
It is a viral vector vaccine that is approximately 90% effective. Covishield is available at several vaccination centres throughout India. The COVID vaccine Covishield has more side effects than the Covaxin vaccination for Corona.

6)Who should avoid taking Covaxin?
COVAXIN® has been approved for limited use in emergency situations in people 18 and older. WHO SHOULDN’T TAKE COVAXIN®? If you have had a severe allergic reaction to any of the vaccine’s ingredients, you should not receive COVAXIN®. After a previous dose of this vaccine, I had a severe allergic reaction.